Valneva announces the sale for $103 million (€95 million) of the priority review warrant it obtained from the US FDA, for its single-injection vaccine for the prevention of disease caused by the chikungunya virus.

The company had received this warrant in November 2023 along with marketing authorization. With this US approval, Ixchiq became the first vaccine in the world to be licensed against chikungunya, an unmet medical need.

Valneva will use the proceeds from the sale of the voucher to fund its R&D projects, including the co-development of its Lyme disease vaccine currently in Phase III and the launch of additional clinical trials for Ixchiq.

Copyright (c) 2024 CercleFinance.com. All rights reserved.